Trade Sino Biopharmaceutical Limited - 1177 CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024571% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.002653% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | HKD | ||||||||
Margin | 5% | ||||||||
Stock exchange | Hong Kong | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Sino Biopharmaceutical Ltd ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.8 |
Open* | 2.76 |
1-Year Change* | -24.59% |
Day's Range* | 2.76 - 2.88 |
52 wk Range | 2.89-5.00 |
Average Volume (10 days) | 36.82M |
Average Volume (3 months) | 940.71M |
Market Cap | 54.90B |
P/E Ratio | 28.10 |
Shares Outstanding | 18.80B |
Revenue | 30.94B |
EPS | 0.10 |
Dividend (Yield %) | 2.73973 |
Beta | 0.67 |
Next Earnings Date | Mar 29, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 2.86 | 0.10 | 3.62% | 2.76 | 2.88 | 2.72 |
Sep 21, 2023 | 2.80 | -0.08 | -2.78% | 2.88 | 2.88 | 2.78 |
Sep 20, 2023 | 2.88 | 0.00 | 0.00% | 2.88 | 2.90 | 2.86 |
Sep 19, 2023 | 2.88 | -0.02 | -0.69% | 2.90 | 2.90 | 2.86 |
Sep 18, 2023 | 2.88 | 0.00 | 0.00% | 2.88 | 2.92 | 2.86 |
Sep 15, 2023 | 2.90 | 0.04 | 1.40% | 2.86 | 2.94 | 2.86 |
Sep 14, 2023 | 2.86 | 0.00 | 0.00% | 2.86 | 2.88 | 2.84 |
Sep 13, 2023 | 2.86 | -0.06 | -2.05% | 2.92 | 2.92 | 2.84 |
Sep 12, 2023 | 2.90 | 0.00 | 0.00% | 2.90 | 2.94 | 2.88 |
Sep 11, 2023 | 2.94 | 0.08 | 2.80% | 2.86 | 2.98 | 2.84 |
Sep 7, 2023 | 2.88 | -0.02 | -0.69% | 2.90 | 2.90 | 2.86 |
Sep 6, 2023 | 2.90 | 0.00 | 0.00% | 2.90 | 2.92 | 2.84 |
Sep 5, 2023 | 2.92 | -0.10 | -3.31% | 3.02 | 3.02 | 2.90 |
Sep 4, 2023 | 3.02 | 0.10 | 3.42% | 2.92 | 3.02 | 2.90 |
Aug 31, 2023 | 2.92 | -0.06 | -2.01% | 2.98 | 3.00 | 2.88 |
Aug 30, 2023 | 2.98 | -0.04 | -1.32% | 3.02 | 3.06 | 2.98 |
Aug 29, 2023 | 3.02 | 0.06 | 2.03% | 2.96 | 3.04 | 2.92 |
Aug 28, 2023 | 2.92 | -0.12 | -3.95% | 3.04 | 3.06 | 2.92 |
Aug 25, 2023 | 2.94 | 0.00 | 0.00% | 2.94 | 3.00 | 2.90 |
Aug 24, 2023 | 2.94 | 0.04 | 1.38% | 2.90 | 2.96 | 2.90 |
Sino Biopharmaceutical Limited Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, October 4, 2023 | ||
Time (UTC) 12:00 | Country HK
| Event Sino Biopharmaceutical Ltd Sino Biopharmaceutical LtdForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 28780.4 | 26861.4 | 23647.2 | 24234 | 20888.6 |
Revenue | 28780.4 | 26861.4 | 23647.2 | 24234 | 20888.6 |
Cost of Revenue, Total | 5795.51 | 5332.1 | 5182.32 | 4926.27 | 4196.93 |
Gross Profit | 22984.9 | 21529.3 | 18464.9 | 19307.8 | 16691.7 |
Total Operating Expense | 22409.8 | 21610.9 | 18307.6 | 18424.9 | 9366.15 |
Selling/General/Admin. Expenses, Total | 12564 | 12763.6 | 11628.6 | 11797 | 10268 |
Interest Expense (Income) - Net Operating | -172.512 | -1110.37 | -963.72 | -561.3 | -568.428 |
Unusual Expense (Income) | 25.527 | 639.276 | -4.58 | -0.903 | -6557.24 |
Other Operating Expenses, Total | -55.912 | 308.971 | -161.711 | -134.863 | -63.724 |
Operating Income | 6370.64 | 5250.5 | 5339.65 | 5809.16 | 11522.4 |
Interest Income (Expense), Net Non-Operating | -592.034 | 13322.2 | -326.601 | -118.565 | -93.354 |
Net Income Before Taxes | 5778.6 | 18572.7 | 5013.04 | 5690.59 | 11429.1 |
Net Income After Taxes | 5002.62 | 16614.8 | 4340.67 | 4787.85 | 10732.8 |
Minority Interest | -2459.05 | -2006.38 | -1569.58 | -2026.3 | -1686.5 |
Net Income Before Extra. Items | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Net Income | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Income Available to Common Excl. Extra. Items | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Income Available to Common Incl. Extra. Items | 2543.57 | 14608.4 | 2771.09 | 2761.54 | 9046.35 |
Diluted Net Income | 2311.2 | 14125.9 | 2771.09 | 2761.54 | 9046.35 |
Diluted Weighted Average Shares | 19017.2 | 19283 | 18800.3 | 18811.1 | 18548.5 |
Diluted EPS Excluding Extraordinary Items | 0.12153 | 0.73256 | 0.1474 | 0.1468 | 0.48771 |
Dividends per Share - Common Stock Primary Issue | 0.10598 | 0.06519 | 0.06172 | 0.04766 | 0.04292 |
Diluted Normalized EPS | 0.12269 | 0.76241 | 0.14719 | 0.14743 | 0.15597 |
Research & Development | 4253.15 | 3677.26 | 2626.71 | 2398.71 | 2090.57 |
Dilution Adjustment | -232.37 | -482.511 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 15277 | 13586.7 | 15193.7 | 26861.4 | 7110.79 |
Revenue | 15277 | 13586.7 | 15193.7 | 26861.4 | 7110.79 |
Cost of Revenue, Total | 3256.5 | 2835.91 | 2959.6 | 5332.1 | 1337.41 |
Gross Profit | 12020.5 | 10750.8 | 12234.1 | 21529.3 | 5773.38 |
Total Operating Expense | 11529.3 | 10636.8 | 11773 | 21610.9 | 5006.58 |
Selling/General/Admin. Expenses, Total | 6444.36 | 5630.1 | 6933.9 | 12703.6 | 3180.71 |
Research & Development | 2357.26 | 2204.55 | 2048.6 | 3677.26 | 767.055 |
Interest Expense (Income) - Net Operating | -137.247 | 17.194 | -189.706 | -818.075 | -181.424 |
Unusual Expense (Income) | -14.761 | -1.162 | 7.288 | -3.731 | -0.794 |
Other Operating Expenses, Total | -376.823 | -49.832 | 13.321 | 719.681 | -96.374 |
Operating Income | 3747.74 | 2949.91 | 3420.73 | 5250.5 | 2104.21 |
Interest Income (Expense), Net Non-Operating | -523.575 | -925.918 | 333.884 | 13322.2 | 6032.95 |
Net Income Before Taxes | 3224.17 | 2023.99 | 3754.61 | 18572.7 | 8137.16 |
Net Income After Taxes | 2699.42 | 1819.4 | 3183.22 | 16614.8 | 7247.19 |
Minority Interest | -1440.64 | -1196.86 | -1262.18 | -2006.38 | -680.348 |
Net Income Before Extra. Items | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Net Income | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Income Available to Common Excl. Extra. Items | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Income Available to Common Incl. Extra. Items | 1258.78 | 622.533 | 1921.04 | 14608.4 | 6566.84 |
Diluted Net Income | 1258.78 | 551.1 | 1760.1 | 14125.9 | 6566.84 |
Diluted Weighted Average Shares | 18564.2 | 18911.7 | 19122.7 | 19283 | 19289.1 |
Diluted EPS Excluding Extraordinary Items | 0.06781 | 0.02914 | 0.09204 | 0.73256 | 0.34044 |
Dividends per Share - Common Stock Primary Issue | 0.01851 | 0.05299 | 0.05122 | 0.03259 | 0.01663 |
Diluted Normalized EPS | 0.06714 | 0.02909 | 0.09237 | 0.73258 | 0.34041 |
Dilution Adjustment | -71.433 | -160.937 | -482.511 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 25934.9 | 23503.2 | 22794.2 | 24913.1 | 18538.1 |
Cash and Short Term Investments | 16921.7 | 15794.1 | 16431.8 | 19105.6 | 13022.7 |
Cash | 6413.98 | 6213.97 | 6596.5 | 4340.18 | 3956.99 |
Cash & Equivalents | 2240.82 | 3385.56 | 4027.69 | 6291.03 | 2278.04 |
Short Term Investments | 8266.86 | 6194.51 | 5807.63 | 8474.34 | 6787.64 |
Total Receivables, Net | 6218.71 | 5537.26 | 4075.75 | 3342.97 | 3865.17 |
Accounts Receivable - Trade, Net | 4638.4 | 4220.67 | 2914.08 | 2712.21 | 2924.04 |
Total Inventory | 2328.84 | 1937.74 | 1880.05 | 1658.6 | 1209.16 |
Prepaid Expenses | 465.687 | 234.127 | 406.578 | 805.972 | 404.009 |
Other Current Assets, Total | 37.116 | ||||
Total Assets | 64064.3 | 60543.3 | 47210.4 | 37514.2 | 49780.2 |
Property/Plant/Equipment, Total - Net | 9251.18 | 8516.06 | 8392.2 | 7633.22 | 5804.37 |
Property/Plant/Equipment, Total - Gross | 13858.3 | 12490.9 | 11475.9 | 10013.8 | 7176.27 |
Accumulated Depreciation, Total | -4607.08 | -3974.82 | -3083.65 | -2380.6 | -1371.91 |
Goodwill, Net | 662.611 | 647.93 | 88.926 | 88.926 | 13897 |
Intangibles, Net | 1251.84 | 1064.02 | 924.71 | 1324.21 | 8349.17 |
Long Term Investments | 25950.3 | 25875.1 | 11215.4 | 2582.92 | 1437.27 |
Other Long Term Assets, Total | 1013.41 | 937.04 | 3795.02 | 971.814 | 1754.29 |
Total Current Liabilities | 20150.7 | 15345 | 10943.5 | 8123.02 | 9668.62 |
Accounts Payable | 1637.35 | 1693.15 | 1947.8 | 1809.44 | 1832.17 |
Accrued Expenses | 6299.15 | 5145.84 | 4190.39 | 3560.56 | 3252.42 |
Notes Payable/Short Term Debt | 136.13 | 136.13 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 9723.84 | 6585.04 | 1581.52 | 689.828 | 2905.57 |
Other Current Liabilities, Total | 2354.2 | 1784.86 | 3223.82 | 2063.19 | 1678.46 |
Total Liabilities | 34317.2 | 30252.2 | 30463.3 | 22564.9 | 20567.4 |
Total Long Term Debt | 4258.12 | 5685.27 | 13067.5 | 7926.07 | 507.066 |
Long Term Debt | 3933.86 | 5365.32 | 12802.6 | 7884.8 | 507.066 |
Deferred Income Tax | 831.791 | 881.59 | 171.652 | 423.261 | 1522.06 |
Minority Interest | 8196.51 | 7437.91 | 5672.4 | 5611.94 | 8336.69 |
Other Liabilities, Total | 880.146 | 902.433 | 608.201 | 480.652 | 532.941 |
Total Equity | 29747 | 30291.1 | 16747.2 | 14949.2 | 29212.8 |
Common Stock | 414.899 | 415.44 | 415.895 | 278.451 | 278.846 |
Additional Paid-In Capital | 12461.4 | 12555.7 | 12668.7 | 12944.4 | 13020.5 |
Retained Earnings (Accumulated Deficit) | 19070.3 | 17926.7 | 4087.38 | 2435.23 | 16462.1 |
Unrealized Gain (Loss) | 93.701 | 533.078 | 400.958 | 37.067 | 287.199 |
Other Equity, Total | -860.86 | -450.393 | -355.848 | -333.099 | -378.576 |
Total Liabilities & Shareholders’ Equity | 64064.3 | 60543.3 | 47210.4 | 37514.2 | 49780.2 |
Total Common Shares Outstanding | 18468.1 | 18839.6 | 18861.5 | 18882.4 | 18910.1 |
Treasury Stock - Common | -1432.48 | -689.347 | -469.944 | -412.837 | -457.288 |
Capital Lease Obligations | 324.263 | 319.949 | 264.861 | 41.27 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 25934.9 | 25197.8 | 23503.2 | 23813.3 | 21790.6 |
Cash and Short Term Investments | 16921.7 | 15674.8 | 15224.6 | 10443.3 | 10336.6 |
Cash | 6413.98 | 4212.46 | 6213.97 | 5576.28 | 5488.38 |
Cash & Equivalents | 2240.82 | 1852.99 | 3385.56 | 2452.05 | 1843.72 |
Short Term Investments | 8266.86 | 9609.39 | 5625.01 | 2415.02 | 3004.5 |
Total Receivables, Net | 5021.14 | 5354.76 | 4625.43 | 5174.74 | 3367.77 |
Accounts Receivable - Trade, Net | 4638.4 | 4947.84 | 4220.67 | 5059.33 | 3250.98 |
Total Inventory | 2328.84 | 2137.13 | 1937.74 | 1731.6 | 1813.05 |
Prepaid Expenses | 1663.26 | 2031.04 | 1715.45 | 6463.63 | 6273.18 |
Total Assets | 64064.3 | 64934.5 | 60543.3 | 56206.7 | 49152.8 |
Property/Plant/Equipment, Total - Net | 9251.18 | 8772.48 | 8516.06 | 8726.67 | 8762.28 |
Goodwill, Net | 662.611 | 642.552 | 647.93 | 906.031 | 890.829 |
Intangibles, Net | 1251.84 | 1214.07 | 1064.02 | 915.743 | 848.788 |
Long Term Investments | 25950.3 | 28168.1 | 25875.1 | 17467.1 | 12674.4 |
Other Long Term Assets, Total | 1013.41 | 939.52 | 937.04 | 4377.86 | 4185.88 |
Total Current Liabilities | 20150.7 | 16265.5 | 15345 | 11485.5 | 10358.5 |
Accounts Payable | 1637.35 | 2676.47 | 1693.15 | 1620.73 | 2161.74 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 9723.84 | 4118.2 | 6585.04 | 1845.84 | 1225.36 |
Other Current Liabilities, Total | 8789.49 | 9470.83 | 7066.83 | 8018.92 | 6971.36 |
Total Liabilities | 34317.2 | 34720.3 | 30252.2 | 31631.1 | 30487.2 |
Total Long Term Debt | 4258.12 | 7983.31 | 5685.27 | 12258.7 | 13038.2 |
Long Term Debt | 3933.86 | 7627.13 | 5365.32 | 11967.4 | 12774.5 |
Capital Lease Obligations | 324.263 | 356.177 | 319.949 | 291.359 | 263.713 |
Deferred Income Tax | 831.791 | 1025.56 | 881.59 | 773.501 | 326.033 |
Minority Interest | 8196.51 | 8530.46 | 7437.91 | 6533.45 | 6186.27 |
Other Liabilities, Total | 880.146 | 915.477 | 902.433 | 579.924 | 578.163 |
Total Equity | 29747 | 30214.2 | 30291.1 | 24575.6 | 18665.6 |
Common Stock | 414.899 | 414.942 | 415.44 | 415.895 | 415.895 |
Retained Earnings (Accumulated Deficit) | 19070.3 | 19267.9 | 17926.7 | 11801 | 18719.7 |
Treasury Stock - Common | -1432.48 | -1378.6 | -689.347 | -469.944 | -469.944 |
Total Liabilities & Shareholders’ Equity | 64064.3 | 64934.5 | 60543.3 | 56206.7 | 49152.8 |
Total Common Shares Outstanding | 18468.1 | 18815.2 | 18839.6 | 18861.5 | 18861.5 |
Additional Paid-In Capital | 12461.4 | 12465.8 | 12555.7 | 12668.7 | |
Unrealized Gain (Loss) | 93.701 | 271.418 | 533.078 | 517.148 | |
Other Equity, Total | -860.86 | -827.306 | -450.393 | -357.207 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 5778.6 | 18572.7 | 5013.04 | 5583.82 | 11429.1 |
Cash From Operating Activities | 6265.15 | 5366.29 | 5325.34 | 5324.63 | 5094.36 |
Cash From Operating Activities | 906.16 | 881.414 | 846.661 | 634.649 | 426.151 |
Amortization | 101.686 | 89.917 | 763.491 | 898.351 | 727.113 |
Non-Cash Items | 642.081 | -12870.8 | -512.005 | -399.094 | -6875.88 |
Cash Taxes Paid | 892.085 | 726.716 | 959.176 | 1102.09 | 838.547 |
Cash Interest Paid | 339.524 | 179.623 | 215.307 | 339.602 | 153.264 |
Changes in Working Capital | -1163.38 | -1306.92 | -785.855 | -1393.09 | -612.103 |
Cash From Investing Activities | -4070.82 | -2515.98 | -7845.56 | -3824.34 | -616.1 |
Capital Expenditures | -1402.68 | -1741.06 | -1495.16 | -1481.14 | -1565.7 |
Other Investing Cash Flow Items, Total | -2668.14 | -774.915 | -6350.4 | -2343.2 | 949.599 |
Cash From Financing Activities | -3186.39 | -3225.26 | 2233.19 | 2800.84 | -2177.74 |
Financing Cash Flow Items | -2014.15 | -452.366 | -1724.7 | -1512.43 | -1167.66 |
Total Cash Dividends Paid | -1267.62 | -938.489 | -1187.02 | -819.688 | -710.328 |
Issuance (Retirement) of Debt, Net | 962.991 | -1501.48 | 5340.28 | 5165.01 | 304.665 |
Foreign Exchange Effects | 47.322 | -649.711 | 280.015 | 95.054 | 242.465 |
Net Change in Cash | -944.732 | -1024.66 | -7.016 | 4396.18 | 2542.99 |
Issuance (Retirement) of Stock, Net | -867.613 | -332.93 | -195.373 | -32.05 | -604.419 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Cash From Operating Activities | 6265.15 | 3948.94 | 5366.29 | 2335.55 | |
Changes in Working Capital | 6265.15 | 3948.94 | 5366.29 | 2335.55 | |
Cash From Investing Activities | -4070.82 | -5989.66 | -2515.98 | -4055.97 | |
Other Investing Cash Flow Items, Total | -2827.49 | -5362.69 | -2515.98 | -4055.97 | |
Cash From Financing Activities | -3186.39 | -1460.53 | -3225.26 | -761.689 | |
Financing Cash Flow Items | -3367.9 | -249.354 | -3225.26 | -761.689 | |
Foreign Exchange Effects | 47.322 | -32.85 | -649.711 | -113.766 | |
Net Change in Cash | -944.732 | -3534.09 | -1024.66 | -2595.87 | |
Capital Expenditures | -1243.32 | -626.972 | |||
Issuance (Retirement) of Stock, Net | -867.613 | -809.316 | |||
Issuance (Retirement) of Debt, Net | 1049.12 | -401.857 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Tse (Eric S Y) | Individual Investor | 21.5412 | 4050000000 | 0 | 2022-12-31 | |
France Investment China 1 Group Ltd | Corporation | 12.1229 | 2279254761 | 0 | 2023-06-30 | |
Tse (Ping) | Individual Investor | 8.8207 | 1658403124 | 27000000 | 2023-07-06 | MED |
Cheng (Cheung Ling) | Individual Investor | 4.718 | 887034750 | 7000000 | 2023-04-04 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.7034 | 320264763 | 430000 | 2023-07-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.1206 | 210679106 | -690000 | 2023-07-31 | LOW |
First Sentier Investors (Hong Kong) Limited | Investment Advisor | 1.0121 | 190293500 | -1957000 | 2023-04-30 | LOW |
Tse (Hsin Stephen) | Individual Investor | 0.9268 | 174247000 | 0 | 2022-12-31 | |
State Street Global Advisors Asia Ltd. | Investment Advisor/Hedge Fund | 0.6738 | 126675943 | 5016808 | 2023-07-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.5832 | 109645878 | -17217700 | 2022-12-31 | LOW |
APG Asset Management N.V. | Pension Fund | 0.5599 | 105263158 | -13607922 | 2023-03-31 | LOW |
Bosera Asset Management Co., Ltd. | Investment Advisor | 0.4681 | 88013000 | 2208000 | 2022-12-31 | LOW |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 0.4668 | 87764104 | 1559585 | 2023-07-31 | LOW |
Hang Seng Investment Management Ltd. | Investment Advisor | 0.4321 | 81233684 | -2624015 | 2023-07-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4245 | 79814490 | 2462000 | 2023-07-31 | LOW |
California Public Employees' Retirement System | Pension Fund | 0.3818 | 71777747 | -5538000 | 2022-06-30 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.377 | 70878477 | 544000 | 2023-07-31 | LOW |
Goldman Sachs Asset Management International | Investment Advisor | 0.3735 | 70221686 | -1817000 | 2023-06-30 | MED |
HSBC Global Asset Management (Hong Kong) Limited | Investment Advisor | 0.3517 | 66124984 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.234 | 44002499 | 625000 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sino Biopharmeceutical Company profile
Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.Industry: | Pharmaceuticals (NEC) |
湾仔港湾道1号会展广场辨公大楼41楼09室
HK
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com